NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

A list of downloadable documents created during development.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Superior rectal artery embolisation for haemorrhoids in ...

the recommendation is unreasonable in the light of the evidence submitted to NICE. NICE’s guide to the technology appraisal and highly specialised technologies appeal process sets out the arrangements ...

For information the company have advised that they will no longer be making a submission, or making this gene therapy available in the UK. Therefore, in collaboration with the company, NICE has ...

The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps ...